Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Income from Continuing Operations of 145101000.0 for Q1 2026, down 358.18% year-over-year from 56201503.97 in Q1 2025, and down 212.88% quarter-over-quarter from 46376000.0 in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Income from Continuing Operations for 7 consecutive years, with 145101000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 358.18% year-over-year to 145101000.0; the TTM figure through Mar 2026 stood at 279772000.0 (down 32.03% YoY), while the FY2025 annual figure was 398134000.0, down 190.41% from the prior year.
- Income from Continuing Operations slipped to 145101000.0 in Q1 2026 per OLMA's latest filing, from 46376000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 25797000.0 in Q3 2022 and bottomed at 145101000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 50773117.65 across 5 years, with a median of 42541000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 78.22% — and 2026, when it tumbled 358.18%.
- Olema Pharmaceuticals' Income from Continuing Operations stood at 26569000.0 in 2022, then fell by 2.1% to 27128000.0 in 2023, then slipped by 24.52% to 33780000.0 in 2024, then tumbled by 37.29% to 46376000.0 in 2025, then plunged by 212.88% to 145101000.0 in 2026.
- Business Quant data shows OLMA's Income from Continuing Operations at 145101000.0 in Q1 2026, 46376000.0 in Q4 2025, and 42541000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | -62.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.67 Mn |
| Mar 31, 2026 | -53.21 Mn |
| Dec 31, 2025 | -46.07 Mn |
| Sep 30, 2025 | -42.23 Mn |
| Jun 30, 2025 | -43.82 Mn |
| Mar 31, 2025 | -30.35 Mn |
| Dec 31, 2024 | -33.47 Mn |
| Sep 30, 2024 | -34.69 Mn |
| Jun 30, 2024 | -30.42 Mn |
| Mar 31, 2024 | -30.99 Mn |
| Dec 31, 2023 | -26.87 Mn |
| Sep 30, 2023 | -21.42 Mn |
| Jun 30, 2023 | -20.05 Mn |
| Mar 31, 2023 | -28.30 Mn |
| Dec 31, 2022 | -26.25 Mn |
| Sep 30, 2022 | -22.60 Mn |
| Jun 30, 2022 | -32.88 Mn |
| Mar 31, 2022 | -23.04 Mn |
| Dec 31, 2021 | -21.65 Mn |
| Sep 30, 2021 | -17.66 Mn |